Drug intelligence / Profile preview

Vendaje

Development stage: Unknown
Lead developer: BioStem Technologies
Administration: Topical

Overview

Vendaje is a dehydrated human amniotic membrane (dHACM) allograft developed by BioStem Technologies for the management of chronic wounds, specifically diabetic foot ulcers (DFU). The product is processed using the proprietary bioREtain method, which involves initial disinfection, processing with isotonic solutions, dehydration at controlled temperatures (37-40°C), and electron beam sterilization. This process is designed to preserve the natural extracellular matrix (ECM) and endogenous growth factors inherent in amniotic tissue. Vendaje functions as a biological scaffold that facilitates wound healing by providing a structural matrix and signaling molecules that support cellular recruitment, migration, and proliferation.

Brand names: Vendaje
Other names: Dehydrated Human Amniotic MembranedHACM

Beyond the preview

Go deeper on Vendaje.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vendaje.

Explore the full profile